1. What is it?
N-acetyl-Selank retains Selank's seven-amino-acid chain with an acetyl group added at its beginning. The primary PubChem record, based partly on FDA GSRS data, describes a form with a free acid end. N-acetyl-Selank amidate means another modification at the opposite end. These forms cannot be equated without checking structure. Selank acetate is a salt, not the same chemical change as N-acetylation. [105] [104]
2. Why do people turn to it?
The expected uses are usually less anxiety, greater calm and better concentration, goals familiar from descriptions of ordinary Selank. The N-acetyl version is also claimed to act more strongly or for longer. No appropriate human studies of this particular molecule were found to support those additional promises. In practice, descriptions often jump from a change in structure to a promise of a noticeable effect. Even findings from small studies of ordinary Selank do not establish what its modified counterpart will do. [105] [98] [99]
3. How does it work?
Changing the end of a peptide may affect its interaction with enzymes and receptors, but the direction and size of the effect need to be measured. Chemical structure alone does not reveal how long it acts in the body. A laboratory study of ordinary Selank found an effect on GABA binding in cell-membrane preparations. However, it did not test N-acetyl-Selank. Whether the latter shares that mechanism, how strong its effect might be and whether it would matter for human symptoms therefore remain unknown. [105] [101]
4. What do studies actually show?
The search completed on 3 November 2026 found no clinical study that clearly administered N-acetyl-Selank and assessed its effectiveness. A 2008 publication, often relevant to descriptions of this family, concerns ordinary Selank. Likewise, comparative studies and papers on combining Selank with phenazepam do not confirm the acetylated version. A sound bibliography may cite them as background, but must clearly state that they did not study the same substance. [98] [99] [100] [105]
5. What do we still not know?
Basic questions remain unanswered: how much reaches the blood and brain, how quickly it breaks down and whether benefits last after use stops. A reliable comparison with unmodified Selank has not been established either. The description improved version is therefore an assumption at this stage, not a research finding. It is particularly easy to overlook the difference between an acetylated variant, a variant that is also amidated and a peptide salt. Combining their data under one name obscures what is actually known. [105] [104]
6. What are the risks?
There is no reliable basis for stating how often N-acetyl-Selank causes adverse effects or claiming that it does not cause dependence, drowsiness or interactions. Such assurances require observation of this exact molecule in humans. A lack of reports in the publications found is not evidence that there are no problems; it may simply reflect a lack of studies. Experience with ordinary Selank in a small patient group also does not cover unknown changes resulting from acetylation or different products made under similar names. [105] [98] [101]
7. Is it an approved medicine?
No document confirming an approved indication for N-acetyl-Selank to treat anxiety or improve memory in Poland was found. The available chemical record identifies the substance; it does not authorise treatment. The FDA explains that UNII identifiers do not mean that it accepts a substance's effectiveness or safety. This also rules out the mistaken assumption that a product is FDA-approved simply because its name appears in an American database. Any status of ordinary Selank in another country does not automatically extend to its derivative. [105] [104]
8. What is new in research?
As of 3 November 2026, the search findings remain unchanged: no direct human results were found for N-acetyl-Selank. A chemical-record update is not a treatment trial and does not change that assessment. Real progress would be a publication specifying the exact structure, methods, health outcomes and adverse effects. Until then, the most accurate account distinguishes what is known about the name and structure from what remains unknown about its effects. [105] [98]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- N-Acetyl selank
Primary chemical identity record in NIH PubChem, CID 133082488, using FDA GSRS data; record modified on 5 September 2026. The sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH, formula and data provenance were reviewed; no clinical data. The direct FDA GSRS page J3PM702O93 did not return readable content. Accessed: 3 November 2026.
- SELANK
FDA Substance Registration System; name, sequence, identifier and the statement that a UNII does not mean drug approval reviewed. Accessed: 3 November 2026.
- [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
2008; primary study in patients with anxiety disorders; Russian article, English abstract; details of randomisation and blinding could not be established from the abstract; PubMed metadata and English abstract reviewed, not the full text. Accessed: 3 November 2026.
- [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
2014; primary comparative study in patients with anxiety disorders; Russian article, English abstract; PubMed metadata and English abstract reviewed, not full text. Accessed: 3 November 2026.
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
2018; primary receptor study using brain-cell membrane preparations; findings not applied to human drug-combination safety; PubMed metadata and English abstract reviewed, not full text · DOI: 10.2174/0929866525666180925144642. Accessed: 3 November 2026.
- [Optimization of the treatment of anxiety disorders with selank]
2015; primary study of Selank combined with phenazepam; Russian article, English abstract read; PubMed metadata and English abstract read, without the full text · DOI: 10.17116/jnevro20151156133-40. Accessed: 03.11.2026.